BB&T Investment Services Inc. raised its holdings in shares of Astrazeneca PLC (NYSE:AZN) by 54.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 23,136 shares of the company’s stock after buying an additional 8,199 shares during the period. BB&T Investment Services Inc.’s holdings in Astrazeneca were worth $782,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the business. Garrison Financial Corp increased its holdings in Astrazeneca by 0.5% during the second quarter. Garrison Financial Corp now owns 18,058 shares of the company’s stock valued at $616,000 after buying an additional 86 shares during the last quarter. Dorsey & Whitney Trust CO LLC increased its holdings in Astrazeneca by 0.7% during the second quarter. Dorsey & Whitney Trust CO LLC now owns 13,315 shares of the company’s stock valued at $454,000 after buying an additional 94 shares during the last quarter. Financial Counselors Inc. increased its holdings in Astrazeneca by 2.7% during the second quarter. Financial Counselors Inc. now owns 6,871 shares of the company’s stock valued at $234,000 after buying an additional 182 shares during the last quarter. FTB Advisors Inc. increased its holdings in Astrazeneca by 3.2% during the second quarter. FTB Advisors Inc. now owns 6,471 shares of the company’s stock valued at $197,000 after buying an additional 200 shares during the last quarter. Finally, Pinnacle Financial Partners Inc. increased its holdings in Astrazeneca by 2.5% during the second quarter. Pinnacle Financial Partners Inc. now owns 9,233 shares of the company’s stock valued at $314,000 after buying an additional 229 shares during the last quarter. 14.75% of the stock is owned by institutional investors and hedge funds.

Astrazeneca PLC (AZN) opened at $32.17 on Tuesday. The firm has a market cap of $83,172.78, a P/E ratio of 7.84, a price-to-earnings-growth ratio of 3.19 and a beta of 0.72. Astrazeneca PLC has a 12-month low of $25.55 and a 12-month high of $35.60. The company has a debt-to-equity ratio of 1.09, a current ratio of 0.94 and a quick ratio of 0.72.

Astrazeneca (NYSE:AZN) last posted its quarterly earnings results on Thursday, November 9th. The company reported $1.12 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.57 by $0.55. Astrazeneca had a net margin of 15.90% and a return on equity of 34.02%. The business had revenue of $6.23 billion during the quarter, compared to analyst estimates of $6 billion. During the same period in the prior year, the business posted $1.32 earnings per share. The company’s revenue was up 9.4% on a year-over-year basis. sell-side analysts anticipate that Astrazeneca PLC will post 1.87 EPS for the current year.

A number of analysts have commented on AZN shares. Citigroup raised shares of Astrazeneca to a “buy” rating in a report on Wednesday, October 18th. Natixis upgraded shares of Astrazeneca from a “neutral” rating to a “buy” rating in a research report on Wednesday, September 6th. Argus reiterated a “buy” rating and issued a $35.00 price target on shares of Astrazeneca in a research report on Friday, September 1st. Investec upgraded shares of Astrazeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, August 9th. Finally, Piper Jaffray Companies reiterated a “buy” rating on shares of Astrazeneca in a research report on Wednesday, August 9th. Four research analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have given a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $34.20.

ILLEGAL ACTIVITY WARNING: This piece was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/12/05/bbt-investment-services-inc-increases-holdings-in-astrazeneca-plc-azn.html.

Astrazeneca Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca PLC (NYSE:AZN).

Institutional Ownership by Quarter for Astrazeneca (NYSE:AZN)

Receive News & Stock Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related stocks with our FREE daily email newsletter.